Skin and fat necrosis of the breast following methylene blue dye injection for sentinel node biopsy in a patient with breast cancer by Salhab, M et al.
BioMed  Central
Page 1 of 3
(page number not for citation purposes)
International Seminars in Surgical 
Oncology
Open Access Case report
Skin and fat necrosis of the breast following methylene blue dye 
injection for sentinel node biopsy in a patient with breast cancer
M Salhab, W Al sarakbi and K Mokbel*
Address: St Georges and The Princess Grace Hospitals, London, UK
Email: M Salhab - msalhab1@excite.com; W Al sarakbi - walsarakbi@hotmail.com; K Mokbel* - kefahmokbel@hotmail.com
* Corresponding author    
Sentinel lymph nodemethylene blue dyebreast cancerskin necrosis
Abstract
Sentinel lymph node biopsy (SLNB) is a simple technique that uses subdermal or peri-tumoral
injection of vital blue dye and/or radioactive isotope to identify the first lymph node(s) draining the
primary tumor. It has been shown to accurately predict axillary node status in patients with
clinically node negative breast cancer. The SLNB is emerging as a new standard of care in patients
with early breast cancer. However, the use of methylene blue (MB) dye can be associated with a
number of local complications due to its tissue reactive properties. We report a rare case of skin
and fat necrosis followed by a dry gangrene of the skin in a female patient with breast cancer who
underwent SLNB localization using peri-tumoral injection of MB dye in another institution. This
case and literature review suggest that the use of MB dye for SLNB identification should be avoided
and replaced with alternative types of blue dye such as Patent Blue V preferably in conjunction with
a radioactive isotope tracer.
Introduction
Sentinel lymph node biopsy (SLNB) is emerging as a new
standard in the treatment of patients with operable breast
cancer. It is a simple technique that uses subdermal or
peri-tumoral injection of vital blue dye and/or radioactive
isotope to identify the first lymph node(s) draining the
primary tumor. SLNB is a reliable and minimally invasive
procedure, which accurately predicts axillary node status
in patients with clinically node negative breast cancer [1].
Localization of the sentinel lymph node using the intra-
dermal, subareolar or peritumoural injection of a vital
blue dye is widely practiced [2]. However, local and sys-
temic complications secondary to the use of the dye have
been reported.
We report a rare case of severe skin and fat necrosis sec-
ondary to the injection of methylene blue dye in a patient
with T1 breast cancer. This complication occurred in a dif-
ferent institution.
Case report
A postmenopausal woman was referred to the senior
author (KM) following breast conserving surgery for 17
mm invasive ductal carcinoma of the right breast. Locali-
zation of the sentinel lymph node was performed using
the dual localization technique. Intradermal injection of
technetium-labled sulphur colloid was performed over
the tumour site. The following day, the patient had the
MB dye injected in the peritumoral area. The operation
was uneventful.
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Three days post operatively and upon removal of the
wound dressing, the lateral aspect of the breast skin exhib-
ited a rectangular erythematous violaceous surface which
developed into a dry gangrenous area a few days later (Fig-
ure 1). We believe that the patient developed skin and fat
necrosis secondary to the MB dye injection. This compli-
cation may have been caused by a localised tissue reaction
initiated by, or involving the dye.
Discussion
The technique of blue dye mapping was first described for
breast cancer by Giuliano et al [3]. Isosulfan blue dye has
been traditionally used the dye used for SLNB for breast
cancer. However, its use was associated with a significant
number of allergic reactions [4], some of which are life
threatening. Because methylene blue dye has been shown
to be equally effective and does not pose a serious risk of
severe allergic and hypersensitivity reactions, it was
regarded as an acceptable substitute for isosulfan blue dye
for SLNB [5-8]. Although, the use of the MB dye for SLNB
in breast cancer has fewer allergic reactions, its use has
been associated with a number of local and systematic
complications. Stradling et al, was the first to report
adverse skin reactions to methylene blue dye in patients
with breast cancer [9]. In addition, skin eruptions and
rashes [10], subcutaneous tissue necrosis and abscess for-
mation [11] have been reported in association with the
injection of this dye. Furthermore, capsular contraction
following breast reconstruction using an implant with
intense blue discoloration of the prosthesis was reported
in a patient in whom methylene blue dye was used to
identify the sentinel lymph node [12].
In our reported case, severe skin and fat necrosis compli-
cated the peri-tumoral injection of methylene blue dye;
This might be due to that methylene blue dye may induce
an early foreign body-type reaction characterized by
ischemic ulceration, fibrinoid necrosis with eosinophilic
infiltration [13].
Therefore, we recommend the use of Patent Blue V dye
instead of MB for SLNB localization in patients with
breast cancer in order to avoid such significant complica-
tions which may delay subsequent treatment. Patent Blue
dye has been reported to cause minor local complications
in form of long-term discoloring of the skin at the site of
injection [14]. Although no cases of severe local tissue
necrosis has been reported in association with Patent Blue
V dye, however, anaphylactic shock has been observed fol-
lowing its injection for SLNB localization [15,16]. The risk
of allergic reactions can be reduced by using corticoster-
oids and antihistamines [4,17,18]
In conclusion, the use of MB dye for SLNB identification
should be avoided and replace with alternative types of
blue dye such as Patent Blue V preferably in conjunction
with a radioactive isotope tracer.
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